Kaynes Technology Shares Tumble 25% in 3 Days After Weak Q4; Elara Cuts Rating to ‘Accumulate’

Why It Matters

The downgrade highlights cash‑flow and working‑capital pressures that could curb Kaynes’ growth, signaling heightened risk for investors in India’s fast‑growing EMS market.

Key Takeaways

• Shares fell ~25% in three days, hitting Rs 3,132.
• Q4 net profit dropped 22% to Rs 91 crore (~$11 M).
• Revenue rose 26% YoY to Rs 1,243 crore (~$150 M).
• Elara cut target price to Rs 3,530 (~$42.5) and rating to Accumulate.
• FY27 growth outlook trimmed to 30%, OCF remains negative.

Pulse Analysis

Kaynes Technology India Ltd saw its shares tumble roughly 25% over three trading sessions after the company posted a weaker‑than‑expected fourth‑quarter. Net profit slipped 22% year‑on‑year to Rs 91 crore, about $11 million, while revenue climbed 26% to Rs 1,243 crore (~$150 million). 7). The sharp sell‑off also pushed the stock below key moving averages, reinforcing a bearish technical outlook.

The quarter’s headline numbers mask deeper operational concerns. Operating cash flow remained negative at Rs 6 billion (≈$72 million), far from the positive cash conversion the company had projected for FY26. Net working capital stretched to 125 days, well above the sub‑100‑day benchmark the firm set, indicating that cash is tied up in inventory and receivables. Management’s FY27 guidance now targets 30% top‑line growth, a downgrade from the earlier 40‑50% range, and the revised revenue outlook of Rs 36 billion (~$433 million) falls short of the Rs 40 billion target, underscoring execution risk. Elara also cut the valuation multiple to 36× FY28 earnings from 42×, reflecting heightened uncertainty.

Despite the downgrade, analysts see a silver lining in Kaynes’ upcoming OSAT (outside‑source‑assembly‑test) plant, slated to boost volumes from FY27 onward and sustain the company’s relatively high margin profile. 9 signals oversold conditions, yet the stock trades below all eight simple moving averages, suggesting further downside pressure. Investors will be watching cash‑flow improvement and working‑capital efficiency as key catalysts for a potential rerating, while the broader EMS sector remains sensitive to global chip demand cycles. A rebound in semiconductor orders could provide the tailwinds needed for Kaynes to hit its FY27 growth target.